Drugs / IMA203
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06946225 | Jul 2025 → Aug 2029 expected | cutaneous melanoma, synovial sarcoma | Immatics US, Inc. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03686124 | May 2019 → Dec 2028 expected | refractory malignant neoplasm | Immatics US, Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06743126 | Jan 2025 → Jan 2028 expected | cutaneous melanoma | Immatics US, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03686124 ↗ |
| Modality | Cell therapy | “IMA203, an autologous preferentially expressed antigen in melanoma (PRAME)-directed TCR T cell therapy in HLA-A*02+ patients with PRAME+ recurrent and/or refractory solid...” PMID 40205198 ↗ Apr 2025 |
| Target | PRAME | “IMA203, an autologous preferentially expressed antigen in melanoma (PRAME)-directed TCR T cell therapy in HLA-A*02+ patients with PRAME+ recurrent and/or refractory solid...” PMID 40205198 ↗ Apr 2025 |